Antitrust implications of COVID-19: FTC Commissioner proposes stopping the “shot clock” on merger reviews

March 20, 2020

Antitrust Alert

Author(s): Brian J. Whittaker, Alycia A. Ziarno, Gordon L. Lang

FTC Commissioner Chopra suggests pausing the waiting period for government review of reportable mergers and acquisitions during national emergencies, such as the COVID-19 pandemic. 

On March 18, 2020, Rohit Chopra, one of five Commissioners of the U.S. Federal Trade Commission (FTC), suggested that the U.S. Congress should enact new legislation or amend current laws, such as the Hart-Scott-Rodino Act (“HSR Act”), to pause the statutory waiting period for government review of mergers and acquisitions during national emergencies, such as the COVID-19 pandemic.

Under the HSR Act, parties to certain mergers and acquisitions must provide the FTC and U.S. Department of Justice (DOJ) with notice and information about their proposed transactions. Thereafter, the parties to a proposed transaction must wait, generally, for an initial period of 30 days, to allow government review before closing. The purpose of the statutory waiting period is to give the government time to assess whether, in its view, the proposed transaction poses any anticompetitive issues.

As disruptions caused by the COVID-19 pandemic continue, Commissioner Chopra recently tweeted, “During a national emergency, corporations shouldn’t be able to dictate how government is using limited resources. Under the current law, companies must give notice before closing a big merger. If government doesn’t act within a certain number of days, the merger goes through.” Commissioner Chopra elaborated in a second tweet by stating, “Corporations shouldn’t be able to slip big mergers through during national emergencies. Congress should stop the shot clock so public servants have enough time to investigate and sue to block bad deals.”[1]

A reactionary change such as that suggested by Chopra would likely result in even more disruptions to businesses who are already grappling with stalled deals during this national emergency. Although the FTC stated earlier this week that review of HSR filings “will continue as normal,”[2] it acknowledged that it “will not be granting” early termination of the HSR waiting period, and it is “reallocating resources” to try to maintain “continuity of core operations” as the COVID-19 pandemic continues.[3]

Due to rapidly changing responses by the government to the COVID-19 pandemic, businesses that are parties to HSR-reportable mergers and acquisitions should consult with their antitrust counsel to remain up-to-date on the new developments and identify appropriate strategies to comply with the HSR Act.

  1. Available at (last visited Mar. 19, 2020).
    [Back to reference]
  2. U.S. Federal Trade Commission, “COVID-19 — Guidance for Filing Parties” (updated Mar. 17, 2020).
    [Back to reference]
  3. Ian Connor, Bureau of Competition, “Changes in Bureau procedure during COVID-19 coronavirus pandemic” (Mar. 16, 2020).
    [Back to reference]

The foregoing has been prepared for the general information of clients and friends of the firm. It is not meant to provide legal advice with respect to any specific matter and should not be acted upon without professional counsel. If you have any questions or require any further information regarding these or other related matters, please contact your regular Nixon Peabody LLP representative. This material may be considered advertising under certain rules of professional conduct.

Back to top